Ghassan Abou-Alfa
Memorial Sloan Kettering Cancer Center · MSKCC · Memorial Sloan-Kettering Cancer Center (MSKCC)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ghassan Abou-Alfa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07265674 · A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd. · recruiting · Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) · principal investigator
- N/ANCT04874519 · Registry to Collect Health Information Related to Fibrolamellar CancerMemorial Sloan Kettering Cancer Center · completed · Fibrolamellar Cancer, FLC, Liver Cancer · principal investigator
- Ph2NCT04000737 · YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)Yiviva Inc. · completed · Advanced Hepatocellular Carcinoma · study chair
- Ph2NCT02234986 · A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCASI pharmaceuticals, Inc. · completed · Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma · study chair
- Ph1NCT02101593 · Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver CancerPolaris Group · completed · Hepatocellular Carcinoma · principal investigator
- Ph2NCT01840592 · Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on SorafenibMemorial Sloan Kettering Cancer Center · active not recruiting · Hepatocellular Carcinoma · principal investigator
- Ph1/Ph2NCT01828034 · First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract CarcinomaMemorial Sloan Kettering Cancer Center · completed · Advanced Biliary Tract Carcinoma · principal investigator
- Ph2NCT01642186 · Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)Memorial Sloan Kettering Cancer Center · completed · Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer · principal investigator
- Ph2NCT00919061 · Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic TherapyMemorial Sloan Kettering Cancer Center · completed · Extrahepatic Bile Duct Cancer, Gallbladder Cancer · principal investigator
- Ph2NCT00639509 · IMC-A12 in Treating Patients With Advanced Liver CancerNational Cancer Institute (NCI) · completed · Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer · principal investigator
- Ph2NCT00087282 · Irinotecan and Flavopiridol in Treating Patients With Advanced Liver CancerMemorial Sloan Kettering Cancer Center · completed · Liver Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2011 to 2026Named on NCT00639509
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:35 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed
- 1,937 citationsRCR 71.8
- 1,499 citationsRCR 109.1
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol · 20201,327 citationsRCR 56.9
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol · 20221,010 citationsRCR 72.7
- 1,001 citationsRCR 22.6
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020931 citationsRCR 37.6
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol · 2018541 citationsRCR 17.7
- 432 citationsRCR 22.7
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.J Clin Oncol · 2021380 citationsRCR 20.2
- 375 citationsRCR 9.4